12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
dc.contributor.author | Tedesco-Silva, Helio | en_US |
dc.contributor.author | Vitko, Stefan | en_US |
dc.contributor.author | Pascual, Julio | en_US |
dc.contributor.author | Eris, Josette | en_US |
dc.contributor.author | Magee, John C. | en_US |
dc.contributor.author | Whelchel, John | en_US |
dc.contributor.author | Civati, Giovanni | en_US |
dc.contributor.author | Campbell, Scott | en_US |
dc.contributor.author | Alves-Filho, Gentil | en_US |
dc.contributor.author | Bourbigot, Bernard | en_US |
dc.contributor.author | Garcia, Valter Duro | en_US |
dc.contributor.author | Leone, John | en_US |
dc.contributor.author | Esmeraldo, Ronaldo | en_US |
dc.contributor.author | Rigotti, Paolo | en_US |
dc.contributor.author | Cambi, Vincenzo | en_US |
dc.contributor.author | Haas, Tomas | en_US |
dc.date.accessioned | 2010-06-01T21:35:40Z | |
dc.date.available | 2010-06-01T21:35:40Z | |
dc.date.issued | 2007-01 | en_US |
dc.identifier.citation | Tedesco-Silva, Helio; Vitko, Stefan; Pascual, Julio; Eris, Josette; Magee, John C.; Whelchel, John; Civati, Giovanni; Campbell, Scott; Alves-Filho, Gentil; Bourbigot, Bernard; Garcia, Valter Duro; Leone, John; Esmeraldo, Ronaldo; Rigotti, Paolo; Cambi, Vincenzo; Haas, Tomas (2007). "12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients." Transplant International 20(1): 27-36. <http://hdl.handle.net/2027.42/74645> | en_US |
dc.identifier.issn | 0934-0874 | en_US |
dc.identifier.issn | 1432-2277 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74645 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17181650&dopt=citation | en_US |
dc.format.extent | 516142 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | Journal compilation 2007 European Society for Organ Transplantation | en_US |
dc.subject.other | Cyclosporine | en_US |
dc.subject.other | Efficacy | en_US |
dc.subject.other | Everolimus | en_US |
dc.subject.other | Renal Transplant | en_US |
dc.subject.other | Safety | en_US |
dc.title | 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | 5 Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | 1 Division of Nephrology, Hospital do Rim e Hipertensao, Sao Paolo, Brazil | en_US |
dc.contributor.affiliationother | 2 Transplant Centre IKEM, Prague, Czech Republic | en_US |
dc.contributor.affiliationother | 3 Servicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spain | en_US |
dc.contributor.affiliationother | 4 Royal Prince Alfred Hospital, Sydney, Australia | en_US |
dc.contributor.affiliationother | 6 Organ Transplant Services, Piedmont Hospital, Atlanta, GA, USA | en_US |
dc.contributor.affiliationother | 7 Divisione Nefrologia e Dialisi, Az. Osp. Niguarda Ca’ Granda, Milano, Italy | en_US |
dc.contributor.affiliationother | 8 Princess Alexandra Hospital, Brisbane, Qld, Australia | en_US |
dc.contributor.affiliationother | 9 Hospital das ClÍnicas – UNICAMP, Campinas, SP, Brazil | en_US |
dc.contributor.affiliationother | 10 Service de Nephrologie, CHU, HÔpital Cavale Blanche, Brest, France | en_US |
dc.contributor.affiliationother | 11 Santa Casa de MisericÓridia de Porto Alegre, RS, Brazil | en_US |
dc.contributor.affiliationother | 12 Lifelink Transplant Institute, Tampa General Hospital, Tampa, FL, USA | en_US |
dc.contributor.affiliationother | 13 Hospital Geral de Fortaleza – Setor de Transplante Renal, Fortaleza, Ceara, Brazil | en_US |
dc.contributor.affiliationother | 14 Department of Medical and Surgical Sciences, Policlinico Hospital, Padua, Italy | en_US |
dc.contributor.affiliationother | 15 Department of Medicine and Nephrology, Maggiore Hospital, Parma, Italy | en_US |
dc.contributor.affiliationother | 16 Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerland | en_US |
dc.identifier.pmid | 17181650 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74645/1/j.1432-2277.2006.00414.x.pdf | |
dc.identifier.doi | 10.1111/j.1432-2277.2006.00414.x | en_US |
dc.identifier.source | Transplant International | en_US |
dc.identifier.citedreference | Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311. | en_US |
dc.identifier.citedreference | Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580. | en_US |
dc.identifier.citedreference | Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 53. | en_US |
dc.identifier.citedreference | Sehgal S. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660. | en_US |
dc.identifier.citedreference | Schuler W, Cottens S, HÄberlin B, et al. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 1996; 64: 36. | en_US |
dc.identifier.citedreference | Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150. | en_US |
dc.identifier.citedreference | Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32. | en_US |
dc.identifier.citedreference | Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323. | en_US |
dc.identifier.citedreference | Hausen B, Boeke K, Berry GJ, et al. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability by staggered simultaneous treatment. Transplantation 1999; 67: 956. | en_US |
dc.identifier.citedreference | Vitko S, Margreiter R, Weimar W, et al. the RAD 201 Study Group. International, double-blind, parallel-group study of the safety and efficacy of Certican TM (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and steroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 474. | en_US |
dc.identifier.citedreference | Kaplan B, Tedesco-Silva H, Mendez R, et al. the RAD 251 Study Group. Abstract 1339. North/South American, double-blind, parallel group study of the safety and efficacy of Certican TM (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and corticosteroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 475. | en_US |
dc.identifier.citedreference | Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first 3 months post-transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion (Neoral ® ). Transplantation 2003; 76: 903. | en_US |
dc.identifier.citedreference | Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626. | en_US |
dc.identifier.citedreference | Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247. | en_US |
dc.identifier.citedreference | Nankivell B, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683. | en_US |
dc.identifier.citedreference | Cockcroft D, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31. | en_US |
dc.identifier.citedreference | Davidson J, Wilkinson A, Dantal J et al. New onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: S3. | en_US |
dc.identifier.citedreference | Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577. | en_US |
dc.identifier.citedreference | Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced exposure cyclosporine in de novo renal transplant recipients: a 3-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332. | en_US |
dc.identifier.citedreference | Lawen J, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37. | en_US |
dc.identifier.citedreference | Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.